Published in:
06-10-2022 | ANCA-Associated Vasculitis | Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)
Off-Label Uses of Rituximab in Dermatology
Published in: Current Dermatology Reports | Issue 4/2022
Login to get accessAbstract
Purpose of Review
Rituximab has transformed the treatment of B-cell malignancies and rheumatoid arthritis in the past 2 decades. More recently, this anti-CD20 monoclonal antibody has seen increasing usage in the field of dermatology. This review highlights the evidence supporting its use in several important dermatologic conditions.
Recent Findings
Key recent findings include the 2018 FDA approval of rituximab for the treatment of moderate-to-severe pemphigus.
Summary
Data from randomized controlled trials have demonstrated the efficacy of rituximab in pemphigus, ANCA-associated vasculitis, and cryoglobulinemic vasculitis. More limited data suggests its use in recalcitrant cases of diseases such as pemphigoid, epidermolysis bullosa acquisita, and dermatomyositis. There is scarce evidence and mixed results for rituximab when studied in cutaneous polyarteritis nodosa and cutaneous lupus erythematosus.